Compare T-Mobile Us Inc (TMUS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Mobile Us Inc vs GeneDx Holdings Corp — how do they compare? T-Mobile Us Inc trades at $190.14 (market cap $211.72B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: T-Mobile Us Inc is far larger — about 117.6× GeneDx Holdings Corp's market cap, and T-Mobile Us Inc pays a 2.09% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| TMUS | WGS | |
|---|---|---|
Market Cap | $211.72B | $1.80B |
Sector | Media | Technology |
52-Week High | $259.01 | $167.51 |
52-Week Low | $167.65 | $34.51 |
Enterprise Value | $329.42B | $1.80B |
Dividend Yield | 2.09% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
